ferric-carboxymaltose has been researched along with Hypocalcemia* in 2 studies
2 other study(ies) available for ferric-carboxymaltose and Hypocalcemia
| Article | Year |
|---|---|
Interaction between ferric carboxymaltose and denosumab causing severe hypocalcaemia and hypophosphataemia in a patient without chronic kidney disease.
Coadministration of ferric carboxymaltose and denosumab may cause hypocalcaemia and hypophosphataemia; however, this interaction is not well-described in the literature and has typically been described in patients with chronic kidney disease (CKD). We present a case of this interaction in a patient without preexisting CKD. We suggest the use of alternative iron preparations and an interval of at least 4 weeks between administrations. Topics: Anemia, Iron-Deficiency; Denosumab; Humans; Hypocalcemia; Hypophosphatemia; Renal Insufficiency, Chronic | 2023 |
[Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
Topics: Aged; Anemia, Iron-Deficiency; Causality; Diabetes Mellitus, Type 2; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hepatitis C, Chronic; Humans; Hypocalcemia; Hypophosphatemia; Infusions, Intravenous; Male; Maltose | 2014 |